SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001549595-23-000042
Filing Date
2023-09-07
Accepted
2023-09-07 07:02:52
Documents
12
Period of Report
2023-09-06
Items
Item 1.01: Entry into a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 8-K nrix-20230906.htm   iXBRL 8-K 28986
  Complete submission text file 0001549595-23-000042.txt   159011

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT nrix-20230906.xsd EX-101.SCH 1901
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT nrix-20230906_lab.xml EX-101.LAB 24851
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT nrix-20230906_pre.xml EX-101.PRE 13046
6 EXTRACTED XBRL INSTANCE DOCUMENT nrix-20230906_htm.xml XML 2824
Mailing Address 1700 OWENS STREET, SUITE 205 SAN FRANCISCO CA 94158
Business Address 1700 OWENS STREET, SUITE 205 SAN FRANCISCO CA 94158 (415) 660-5320
Nurix Therapeutics, Inc. (Filer) CIK: 0001549595 (see all company filings)

IRS No.: 270838048 | State of Incorp.: DE | Fiscal Year End: 1130
Type: 8-K | Act: 34 | File No.: 001-39398 | Film No.: 231240945
SIC: 2834 Pharmaceutical Preparations